PharmacoEconomics

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure
PharmacoEconomics - Tập 29 - Trang 753-769 - 2012
Alexander Goehler, Benjamin P. Geisler, Jennifer M. Manne, Beate Jahn, Annette Conrads-Frank, G. Scott Gazelle, Uwe Siebert
Chronic heart failure (CHF) is a critical public health issue with increasing effect on the healthcare budgets of developed countries. Various decisionanalytic modelling approaches exist to estimate the cost effectiveness of health technologies for CHF. We sought to systematically identify these models and describe their structures. We performed a systematic literature review in MEDLINE/PreMEDLINE...... hiện toàn bộ
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
PharmacoEconomics - - 2023
Nancy Devlin, Tianxin Pan, Mark Sculpher, Mark Jit, Elly Stolk, Donna Rowen, Ben van Hout, Richard Norman
Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries
PharmacoEconomics - Tập 19 - Trang 767-778 - 2012
Ola Ghatnekar, Ulf Persson, Michael Willis, Knut Ödegaard
Objective: The primary objective of this study was to estimate the cost effectiveness of treating diabetic foot ulcers with becaplermin (Regranex®) plus good wound care (GWC) compared with GWC alone in a variety of European healthcare settings. A secondary objective was to analyse the effect of different treatment practices on the economics of caring for diabetic foot ulcers. ...... hiện toàn bộ
Retrospective Economic and Outcomes Analyses Using Non-US Databases
PharmacoEconomics - - 2007
Lizheng Shi, Eric Q. Wu, Meredith Hodges, Andrew P. Yu, Howard G. Birnbaum
Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era
PharmacoEconomics - Tập 28 - Trang 17-34 - 2012
Mark A. Boyd, Andrew M. Hill
Despite the success of combination antiretroviral therapy (ART) in improving clinical outcomes, treatment failure remains a significant challenge, particularly for highly treatment-experienced patients. This review evaluates current issues in the management of HIV-infected, treatment-experienced patients. It may provide guidance in selecting active, tolerable drug combinations that promote a reaso...... hiện toàn bộ
Healthcare Costs and Obesity Prevention
PharmacoEconomics - Tập 27 - Trang 1031-1044 - 2012
David R. Rappange, Werner B. F. Brouwer, Rudolf T. Hoogenveen, Pieter H. M. Van Baal
Background: Obesity is a major contributor to the overall burden of disease (also reducing life expectancy) and associated with high medical costs due to obesity-related diseases. However, obesity prevention, while reducing obesity-related morbidity and mortality, may not result in overall healthcare cost savings because of additional costs in life-years gained. Sector-specific fi...... hiện toàn bộ
Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence
PharmacoEconomics - Tập 28 - Trang 347-349 - 2012
Mark Sculpher
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
PharmacoEconomics - Tập 33 - Trang 255-269 - 2014
Mike Paulden, Tania Stafinski, Devidas Menon, Christopher McCabe
The rate of development of new orphan drugs continues to grow. As a result, reimbursing orphan drugs on an exceptional basis is increasingly difficult to sustain from a health system perspective. An understanding of the value that societies attach to providing orphan drugs at the expense of other health technologies is now recognised as an important input to policy debates. The aim of this work wa...... hiện toàn bộ
Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Tập 35 - Trang 415-424 - 2016
Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham, M. Satish Kumar
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures cabazitaxel (Jevtana®, Sanofi, UK) to submit evidence for the clinical and cost effectiveness of cabazitaxel for treatment of patients with metastatic hormone-relapsed prostate cancer (mHRPC) previously treated with a docetaxel-containing regi...... hiện toàn bộ
Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Tập 34 - Trang 1241-1253 - 2016
Rachid Rafia, Alison Scope, Sue Harnan, John W. Stevens, Matt Stevenson, Alan Lobo
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe, active Crohn’s disease. The School of Health and Related Research (ScHARR) at the University ...... hiện toàn bộ
Tổng số: 2,573   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10